GlassScriptPhysician profile
Jessica Coleman
NPI 1992218986
$5,345.54
in general payments reported to CMS, 2019-2025
29 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $260 · 2022: $597 · 2023: $1,564 · 2024: $1,609 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,488.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $924.72 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $869.11 | 2022-2025 | |
| Axsome Therapeutics, INC. | $541.06 | 2022-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $515.25 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $435.24 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Novo Nordisk INC | $420.29 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $411.54 | 2021-2025 | Spravato, Invega Sustenna |
| Lilly USA, LLC | $235.29 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Eisai INC. | $123.46 | 2021-2024 | |
| Genzyme Corporation | $123.08 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $120.00 | 2022 | |
| Vanda Pharmaceuticals INC. | $82.97 | 2021-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.88 | 2021-2023 | |
| Medtronic, INC. | $58.01 | 2023 | Venaseal |
| Bausch Health US, LLC | $51.50 | 2024-2025 | Aplenzin, Wellbutrin |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $43.06 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $41.06 | 2024-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $40.49 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $38.27 | 2024 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.80 | 2025 | Jardiance |
| Ionis Pharmaceuticals, INC. | $22.95 | 2025 | Tryngolza |
| Neurocrine Biosciences, INC. | $21.88 | 2025 | |
| Noven Therapeutics, LLC | $21.04 | 2024 | Secuado, Xelstrym |
| Masimo Corporation | $20.60 | 2023 | Emma and Isa |
| Exact Sciences Corporation | $18.99 | 2025 | The Cologuard Plus Collection Kit |
| Abbott Laboratories | $18.75 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $16.34 | 2023 | |
| Inspire Medical Systems, INC. | $15.99 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $13.92 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.